Delving into the Latest Updates on Demotech, Inc. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Chemical drugs	1

单次给药：主要目的：比较中国健康受试者单次使用DM0201贴与Lidoderm®的药代动力学特征；次要目的：比较DM0201贴与Lidoderm®在中国健康受试者中单次给药的安全性、耐受性与粘附性。多次给药：主要目的：比较中国健康受试者多次使用DM0201贴与Lidoderm®的药代动力学特征；次要目的：比较DM0201贴与Lidoderm®在中国健康受试者中多次给药的安全性、耐受性与粘附性。

[Translation]

Single administration: Primary purpose: To compare the pharmacokinetic characteristics of DM0201 patch and Lidoderm® in Chinese healthy subjects after single administration; Secondary purpose: To compare the safety, tolerability and adhesion of DM0201 patch and Lidoderm® in Chinese healthy subjects after single administration. Multiple administration: Primary purpose: To compare the pharmacokinetic characteristics of DM0201 patch and Lidoderm® in Chinese healthy subjects after multiple administration; Secondary purpose: To compare the safety, tolerability and adhesion of DM0201 patch and Lidoderm® in Chinese healthy subjects after multiple administration.

Start Date26 Oct 2024

Sponsor / Collaborator

Yabao Pharmaceutical Co. Ltd. Beijing

[+1]

CTR20260516

/ Not yet recruitingPhase 2

DM0201贴治疗带状疱疹后神经痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂平行对照临床试验

[Translation] A multicenter, randomized, double-blind, active-drug and placebo-controlled parallel clinical trial to investigate the efficacy and safety of DM0201 patch in treating postherpetic neuralgia.

主要目的：评估DM0201贴治疗带状疱疹后神经痛的有效性。次要目的：评估DM0201贴治疗带状疱疹后神经痛的安全性及粘附性。探索性目的：DM0201贴在II期患者中给药后的残药量。

[Translation]

Primary objective: To evaluate the efficacy of DM0201 patch in treating postherpetic neuralgia. Secondary objective: To evaluate the safety and adhesion of DM0201 patch in treating postherpetic neuralgia. Exploratory objective: To determine the residual amount of DM0201 patch after administration in stage II patients.

Start Date-

Sponsor / Collaborator

Yabao Pharmaceutical Co. Ltd. Beijing

[+1]

100 Clinical Results associated with Demotech, Inc.

Login to view more data

0 Patents (Medical) associated with Demotech, Inc.

Login to view more data

100 Deals associated with Demotech, Inc.

Login to view more data

100 Translational Medicine associated with Demotech, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

3

IND Approval

Phase 2

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DM-0201	Neuralgia, Postherpetic More	Phase 2
DM2080	Arthritis, Gouty More	IND Approval
DM0852	Soft tissue pain More	IND Approval
DM2065	Osteoarthritis More	IND Approval